Drug Response Assessment
Drug Response Assessment - Related Videos
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
09:25
Assessment of Ultrasonic Vocalizations During Drug Self-administration in Rats
0 Views •
Cited by 17 •
2010
Drug self-administration and ultrasonic vocalizations (USV) are used as behavioral assessments in animal research, but rarely in combination. The purpose of this article is to describe the advantages of recording USVs during drug self-administration procedures to assess affective responses to drug experience.
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
0 Views •
Cited by 121 •
2017
This protocol describes an assay for measuring CFTR function and CFTR modulator responses in cultured tissue from subjects with cystic fibrosis (CF). Biopsy-derived intestinal organoids swell in a cAMP-driven fashion, a response that is defective (or strongly reduced) in CF organoids and can be restored by exposure to CFTR modulators.
01:21
Factors Affecting Drug Response: Overview
0 Views •
2023
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
0 Views •
Cited by 48 •
2015
Here we describe a technique to cannulate the mesenteric lymph duct in rats which enables quantification of lipid and drug transport via the lymphatic system following intestinal delivery. The technique can be adapted to assess mesenteric lymph concentrations and/or transport of fluid, immune cells, peptides, proteins and lipophilic molecules.
FAQs
A response profile depends on both the drug concentration and the interval during which the model is exposed. Investigators measure outcomes across defined combinations rather than relying on a single condition, then construct dose-response relationships. This design helps reveal whether inhibition changes with increasing exposure and supports estimation of the IC50, the concentration associated with a half-maximal inhibitory effect.
Readouts should match the biological question. Cell viability indicates how many cells remain functionally alive, whereas proliferation reflects continued cell expansion. Apoptosis measures a programmed cell-death outcome, and molecular markers can reveal drug-associated biological changes. Using more than one readout can provide complementary evidence, helping investigators distinguish reduced growth from other cellular responses.
Variation among cancer subtypes and patient-derived models can change the observed response to the same compound. Drug response assessment makes these differences measurable by applying comparable concentration and time conditions, then comparing efficacy-related outcomes. Such comparisons can expose response variability that may be relevant to treatment optimization and to investigating why some models respond less strongly.
The assessment can track therapeutic effects alongside adverse responses in the tested cells, tissues, or organisms. Measuring outcomes such as viability, proliferation, apoptosis, and molecular markers gives researchers several ways to characterize what the compound does under defined conditions. Considering efficacy and toxicity together supports more informed compound screening and treatment optimization rather than selecting candidates on inhibition alone.
Investigators first select a tumor model, set defined drug concentrations and exposure intervals, and then quantify one or more outcomes. Measurements may include viability, proliferation, apoptosis, or molecular markers. Results are organized into dose-response relationships, allowing the team to compare conditions and estimate response metrics such as IC50 for the tested model.
It is useful during compound screening, when researchers need to compare candidate effects; during treatment optimization, when concentration-dependent outcomes must be evaluated; and when comparing cancer subtypes or patient-derived models. The resulting patterns can also support investigation of resistance mechanisms and contribute to development of more personalized therapeutic strategies.